The relationship of longitudinal change in reproductive hormones and vasomotor symptoms during the menopausal transition.

Authors: Randolph JF, Sowers MF, Bondarenko I, Gold EB, Greendale GA, Bromberger JT, Brockwell SE, Matthews KA. Publication Year: 2005 Citation: J Clin Endocrinol Metab 2005;90(11):6106-12. Vasomotor symptoms are experienced by 65-76% of women going through menopause.  This study examined longitudinal changes in estradiol, FSH, testosterone, DHEA, sex hormone binding globulin, free estrogen index and …

Testosterone for low libido in postmenopausal women not using systemic oestrogen therapy.

Author: Davis SR Publication Year: 2009 Citation: Med J Aust. 2009; 191(3):134-5. This editorial, written by the principal investigator for the “Aphrodite” study, concludes that the use of transdermal testosterone for hypoactive sexual desire disorder (HSDD) shows promising results but long-term safety requires further study.  The article describes the Aphrodite study, in which 814 women with …

The safety of 52 weeks of oral DHEA therapy for postmenopausal women.

Authors: Panjari M, Bell RJ, Jane F, Adams J, Morrow C, Davis SR. Publication Year: 2009 Citation: Maturitas. 2009; 63(3):240-5. In this study, 93 postmenopausal women received either 50 mg/day DHEA or placebo for 52 weeks.  No significant changes, either beneficial or adverse, were seen in the lipid profile (HDL, LDL, total cholesterol and triglycerides), the endometrium, …

The role of testosterone in the management of hypoactive sexual desire disorder in postmenopausal women.

Authors: Krapf JM, Simon JA. Publication Year: 2009 Citation: Maturitas. 2009; 63(3):213-9. This article reviews testosterone’s role in sexual function in women.  Research is going on to study the safety and effectiveness of transdermal testosterone therapy in women with low sexual desire, sometimes called HSDD (hypoactive sexual desire disorder) if it leads to distress.  The prevalence of …

Part 3 – The science behind bioidentical hormone replacement therapy.

Author: Wepfer ST Publication Year: 2002 Citation: Int J Pharm Compounding 2002;6(2):142-6 Differences between synthetic progestins and bioidentical progesterone in terms of their effects on breast cancer risk, estrogen dominance, and vasomotor symptoms are discussed.  The review also covers the use of testosterone for postmenopausal women who have androgen deficiency because of surgically induced menopause.  Androgen …